Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $4.6M Series B financing, bringing the total round to $27.5M. Participants include Roche Venture Fund, Enterprise Ireland, Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.